Sign up
Pharma Capital

Drug at centre of Silence Therapeutics legal action added to UK Early Access to Medicines Scheme

“With regards to IP and patents, Silence will vigorously enforce its patent estate where third parties are considered to be infringing the company's patent rights," said Silence chief executive, Dr David Horn Solomon
judge's gave ad scales
The case goes to court in December with a ruling expected in early 2019

A drug that is the focus of legal action by Silence Therapeutics PLC (LON:SLN) has been granted limited approval here in the UK.

Patisiran, a new-breed of RNAi medicine developed by American biotech Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), will join the Early Access to Medicines Scheme.

READ: Silence Therapeutics names experienced biotech boss as its new chief executive officer

This means Britons with a rare neuro-degenerative disease can receive the treatment before it gains EU marketing authorisation.

Patisiran is at the centre of a court case, set for trial in December, with Silence Therapeutics claiming it infringes intellectual property (IP) the UK life sciences group developed and owns.

“With regards to IP and patents, Silence will vigorously enforce its patent estate where third parties are considered to be infringing the company's patent rights," said chief executive, Dr David Horn Solomon.

View full SLN profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.